Idorsia Ltd (LON:0RQE)

Market Cap	236.92M
Revenue (ttm)	99.17M
Net Income (ttm)	-232.49M
Shares Out	n/a
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,164
Average Volume	11,002
Open	1.117
Previous Close	1.134
Day's Range	1.084 - 1.134
52-Week Range	2.869 - 17.800
Beta	1.55
RSI	57.57
Earnings Date	Apr 30, 2025

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQE

Financial Performance

In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.

Financial numbers in CHF